Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome:: The role of lopinavir-ritonavir-didanosine

被引:110
作者
Rollot, F
Nazal, EM
Chauvelot-Moachon, L
Kélaïdi, C
Daniel, N
Saba, M
Abad, S
Blanche, P
机构
[1] Hop Cochin, Ctr Pharmacovigilance, F-75674 Paris, France
[2] Cochin & St Vincent de Paul Hosp, Ctr Pharmacovigilance, F-75674 Paris, France
关键词
D O I
10.1086/379829
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Tenofovir- related tubular damage, like all other recently reported cases, occurred in patients receiving the protease inhibitor ( PI) ritonavir, often with lopinavir. Increased plasma concentrations of didanosine were also observed after the addition of tenofovir. It was suspected that tenofovir with PIs interacted with renal organic anion transporters, leading to nephrotoxic tubular concentrations of tenofovir and systemic accumulation of didanosine. Until there is a better understanding of these interactions, close monitoring is recommended for patients receiving tenofovir, PIs, and didanosine.
引用
收藏
页码:E174 / E176
页数:3
相关论文
共 15 条
[1]   Renal lesions in HIV-1-positive patient treated with tenofovir [J].
Créput, C ;
Gonzalez-Canali, G ;
Hill, G ;
Piketty, C ;
Kazatchkine, M ;
Nochy, D .
AIDS, 2003, 17 (06) :935-937
[2]  
CROWTHER MA, 1993, AIDS, V7, P131, DOI 10.1097/00002030-199301000-00025
[3]   Interactions of HIV protease inhibitors with ATP-dependent drug export proteins [J].
Gutmann, H ;
Fricker, G ;
Drewe, J ;
Toeroek, M ;
Miller, DS .
MOLECULAR PHARMACOLOGY, 1999, 56 (02) :383-389
[4]  
Ho ES, 2000, J AM SOC NEPHROL, V11, P383, DOI 10.1681/ASN.V113383
[5]   Drug-induced Fanconi's syndrome [J].
Izzedine, H ;
Launay-Vacher, V ;
Isnard-Bagnis, C ;
Deray, G .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (02) :292-309
[6]   Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: Three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus [J].
Karras, A ;
Lafaurie, M ;
Furco, A ;
Bourgarit, A ;
Droz, D ;
Sereni, D ;
Legendre, C ;
Martinez, F ;
Molina, JM .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (08) :1070-1073
[7]  
KEARNEY BP, 2002, 6 INT C DRUG THER HI, P72
[8]  
KEARNEY BP, 2003, 10 C RETR OPP INF BO, P245
[9]  
Miller DS, 2001, J PHARMACOL EXP THER, V299, P567
[10]   Fatal lactic acidosis and acute renal failure after addition of tenofovir to an Antiretroviral regimen containing Didanosine [J].
Murphy, MD ;
O'Hearn, M ;
Chou, SW .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (08) :1082-1085